Integrin-α10 dependency identifies RAC and rictor as therapeutic targets in high-grade myxofibrosarcoma Academic Article uri icon

Overview

MeSH Major

  • Carrier Proteins
  • Fibrosarcoma
  • Integrin alpha Chains
  • rac GTP-Binding Proteins

abstract

  • Identifying the molecular pathogenesis for myxofibrosarcoma progression has proven challenging given the highly complex genomic alterations in this tumor type. We found that integrin-α10 promotes tumor cell survival through activation of TRIO-RAC-RICTOR-mTOR signaling, and that inhibitors of RAC and mTOR have antitumor effects in vivo, thus identifying a potential treatment strategy for patients with high-risk myxofibrosarcoma. Cancer Discov; 6(10); 1148-65. ©2016 AACR.This article is highlighted in the In This Issue feature, p. 1069.

publication date

  • October 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5050162

Digital Object Identifier (DOI)

  • 10.1158/2159-8290.CD-15-1481

PubMed ID

  • 27577794

Additional Document Info

start page

  • 1148

end page

  • 1165

volume

  • 6

number

  • 10